Glucose metabolism derangements in adults with the MELAS m.3243A>G mutation

Mitochondrion

Volumn 18, Issue , 2014, Pages 63-69

  El Hattab, Ayman W ^a,b   Emrick, Lisa T ^a,c   Hsu, Jean W ^a   Chanprasert, Sirisak ^a,c   Jahoor, Farook ^a   Scaglia, Fernando ^a,c   Craigen, William J ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TAWAM HOSPITAL   (United Arab Emirates)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Diabetes; Gluconeogenesis; Insulin resistance; Mitochondrial diseases; Stable isotope infusion

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LACTIC ACID; ORAL ANTIDIABETIC AGENT; LEUCINE TRANSFER RNA;

ADULT; ARTICLE; CLEARANCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET THERAPY; FEMALE; GENE MUTATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLEARANCE RATE; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; GLYCOGENOLYSIS; HEMOGLOBIN BLOOD LEVEL; HETEROPLASMY; HUMAN; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LACTATE BLOOD LEVEL; LACTIC ACIDEMIA; MALE; MELAS SYNDROME; MITOCHONDRIAL GENE; DEFICIENCY; GENETICS; ISOTOPE LABELING; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; POINT MUTATION;

ADULT; DIABETES MELLITUS; FEMALE; GENES, MITOCHONDRIAL; GLUCONEOGENESIS; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; ISOTOPE LABELING; MALE; MELAS SYNDROME; MIDDLE AGED; POINT MUTATION; RNA, TRANSFER, LEU;

EID: 84911454067     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2014.07.008     Document Type: Article

References (38)

1. Ahmadian M., Suh J.M., Hah N., Liddle C., Atkins A.R., Downes M., et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat. Med. 2013, 19:557-566.
2. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32:S62-S67.
3. Azevedo O., Vilarinho L., Almeida F., Ferreira F., Guardado J., Ferreira M., et al. Cardiomyopathy and kidney disease in a patient with maternally inherited diabetes and deafness caused by the 3243A>G mutation of mitochondrial DNA. Cardiology 2010, 115:71-74.
4. Bai R.K., Wong L.J. Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. Clin. Chem. 2004, 50:996-1001.
5. Balasubramanyam A., McKay S., Nadkarni P., Rajan A.S., Garza A., Pavlik V., et al. Ethnicity affects the postprandial regulation of glycogenolysis. Am. J. Physiol. 1999, 277:905-914.
6. Brändle M., Lehmann R., Maly F.E., Schmid C., Spinas G.A. Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation. Diabetes Care 2001, 24:1253-1258.
7. Chinnery P.F., Turnbull D.M. Epidemiology and treatment of mitochondrial disorders. Am. J. Med. Genet. 2001, 106:94-101.
8. Chinnery P.F., Howell N., Lightowlers R.N., Turnbull D.M. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain 1997, 120:1713-1721.
9. Damian M.S., Seibel P., Reichmann H., Schachenmayr W., Laube H., Bachmann G., et al. Clinical spectrum of the MELAS mutation in a large pedigree. Acta Neurol. Scand. 1995, 92:409-415.
10. de Laat P., Koene S., van den Heuvel L.P., Rodenburg R.J., Janssen M.C., Smeitink J.A. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A>G mutation. J. Inherit. Metab. Dis. 2012, 35:1059-1069.
11. de Laat P., Koene S., van den Heuvel L.P., Rodenburg R.J., Janssen M.C., Smeitink J.A., et al. Glucose kinetics and pregnancy outcome in Indian women with low and normal body mass indices. Eur. J. Clin. Nutr. 2009, 63:1327-1334.
12. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996, 19:278-286.
13. El-Hattab A.W., Hsu J.W., Emrick L.T., Wong L.J., Craigen W.J., Jahoor F., et al. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol. Genet. Metab. 2012, 105:607-614.
14. El-Hattab A.W., Emrick L.T., Craigen W.J., Scaglia F. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. Mol. Genet. Metab. 2012, 107:247-252.
15. El-Hattab A.W., Emrick L.T., Chanprasert S., Craigen W.J., Scaglia F. Mitochondria: role of citrulline and arginine supplementation in MELAS syndrome. Int. J. Biochem. Cell Biol. 2014, 48:85-91.
16. Frederiksen A.L., Jeppesen T.D., Vissing J., Schwartz M., Kyvik K.O., Schmitz O., et al. High prevalence of impaired glucose homeostasis and myopathy in asymptomatic and oligosymptomatic 3243A>G mitochondrial DNA mutation-positive subjects. J. Clin. Endocrinol. Metab. 2009, 94:2872-2879.
17. Goto Y., Nonaka I., Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990, 348:651-653.
18. Haymond M.W., Sunehag A.L. The reciprocal pool model for the measurement of gluconeogenesis by use of [U-(13)C]glucose. Am. J. Physiol. Endocrinol. Metab. 2000, 278:E140-E145.
19. Hirano M., Pavlakis S.G. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J. Child Neurol. 1994, 9:4-13.
20. Hirano M., Ricci E., Koenigsberger M.R., Defendini R., Pavlakis S.G., DeVivo D.C., et al. MELAS: an original case and clinical criteria for diagnosis. Neuromuscul. Disord. 1992, 2:125-135.
21. Jeppesen T.D., Schwartz M., Frederiksen A.L., Wibrand F., Olsen D.B., Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. Arch. Neurol. 2006, 63:1701-1706.
22. Jonk A.M., Houben A.J., de Jongh R.T., Serné E.H., Schaper N.C., Stehouwer C.D. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda) 2007, 22:252-260.
23. Kobayashi Y., Momoi M.Y., Tominaga K., Momoi T., Nihei K., Yanagisawa M., et al. A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochem. Biophys. Res. Commun. 1990, 173:816-822.
24. Koga Y., Akita Y., Nishioka J., Yatsuga S., Povalko N., Tanabe Y., et al. l-Arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005, 64:710-712.
25. Lev D., Nissenkorn A., Leshinsky-Silver E., Sadeh M., Zeharia A., Garty B.Z., et al. Clinical presentations of mitochondrial cardiomyopathies. Pediatr. Cardiol. 2004, 25:443-450.
26. Ma Y., Fang F., Cao Y., Yang Y., Zou L., Zhang Y., et al. Clinical features of mitochondrial DNA m.3243A>G mutation in 47 Chinese families. J. Neurol. Sci. 2010, 291:17-21.
27. Maassen J.A., 'T Hart L.M., Van Essen E., Heine R.J., Nijpels G., Jahangir Tafrechi R.S., et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 2004, 53:S103-109.
28. Manwaring N., Jones M.M., Wang J.J., Rochtchina E., Howard C., Mitchell P., et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007, 7:230-233.
29. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E15-E26.
30. Ohkubo K., Yamano A., Nagashima M., Mori Y., Anzai K., Akehi Y., et al. Mitochondrial gene mutations in the tRNA(Leu(UUR)) region and diabetes: prevalence and clinical phenotypes in Japan. Clin. Chem. 2001, 47:1641-1648.
31. Sproule D.M., Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann. N. Y. Acad. Sci. 2008, 1142:133-158.
32. Szendroedi J., Phielix E., Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2011, 8:92-103.
33. Thame M.M., Fletcher H.M., Baker T.M., Jahoor F. Comparing the glucose kinetics of adolescent girls and adult women during pregnancy. Am. J. Clin. Nutr. 2010, 91:604-609.
34. van den Ouweland J.M., Lemkes H.H., Ruitenbeek W., Sandkuijl L.A., de Vijlder M.F., Struyvenberg P.A., et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat. Genet. 1992, 1:368-371.
35. Velho G., Byrne M.M., Clément K., Sturis J., Pueyo M.E., Blanché H., et al. Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Diabetes 1996, 45:478-487.
36. Vionnet N., Passa P., Froguel P. Prevalence of mitochondrial gene mutations in families with diabetes mellitus. Lancet 1993, 342:1429-1430.
37. Wallace D.C. Mitochondrial diseases in man and mouse. Science 1999, 283:1482-1488.
38. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.